No Data
Express News | Bluebird bio Inc : Leerink Partners Raises Target Price to $10 From $1
Bluebird Bio Is Maintained at Overweight by Barclays
Bluebird Bio Analyst Ratings
Barclays Maintains Bluebird Bio(BLUE.US) With Buy Rating, Maintains Target Price $40
Bluebird Bio, Inc. (BLUE): Is This Gene Therapy Stock a Good Buy Right Now?
Investor Optimism Abounds Bluebird Bio, Inc. (NASDAQ:BLUE) But Growth Is Lacking
玄学炒股的美股韭菜 : Already all-in.